Please note that the URL for this site has changed to a 'phe.org.uk' address from 'nhs.uk'. This reflects changes we have made to hosting for this site.
 

The UK NSC recommendation on Fetomaternal and Neonatal Alloimmune Thrombocytopenia (FMAIT) screening (currently under review)

 

This recommendation is currently being reviewed as part of the UK NSC's regular review cycle of all policies.

The review process began in Mar 2016 and is estimated to be completed by Feb 2017.

Recommendation Systematic population screening programme not recommended
 
Key downloads
 

Find general information about population health screening.

More about FMAIT

When an unborn baby's platelets (cells necessary for blood clotting) are not recognised by the mother's body, she sometimes makes antibodies which attack the baby's platelets (Fetomaternal alloimmune thrombocytopenia, FMAIT). This causes bleeding in the baby in the womb or shortly after birth. Babies can be at serious risk of brain damage or death.

Stakeholders

BLISS
British Committee for Standards in Haematology (BCSH)
British Paediatric Allergy, Immunology and Infection Group
Brtish Association of Perinatal Medicine
Faculty of Public Health
NAIT Babies
NHS Blood & Transplant
Royal College of General Practitioners
Royal College of Midwives
Royal College of Obstetricians and Gynaecologists
Royal College of Paediatrics and Child Health
UK Newborn Screening Laboratories Network

The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.

Related documents

icon Summary of Policy Recommendation and Consultation responses for FMAIT 250713 (PDF document, 42KB, 26/07/13)

More options

Go to top